Form 3 - Initial statement of beneficial ownership of securities:
SEC Accession No. 0000950170-25-008960
Filing Date
2025-01-24
Accepted
2025-01-24 20:00:05
Documents
2
Period of Report
2025-01-22

Document Format Files

Seq Description Document Type Size
1 3 ownership.html 3  
1 3 ownership.xml 3 1638
2 EX-24 kytx-ex24.htm EX-24 11704
  Complete submission text file 0000950170-25-008960.txt   14809
Mailing Address 5980 HORTON STREET SUITE 550 EMERYVILLE CA 94608
Business Address 5980 HORTON STREET SUITE 550 EMERYVILLE CA 94608 5106268331
Kyverna Therapeutics, Inc. (Issuer) CIK: 0001994702 (see all company filings)

EIN.: 831365441 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)

Mailing Address C/O PAUL HASTINGS LLP 200 PARK AVENUE NEW YORK NY 10166
Business Address
GEHCHAN NAJI (Reporting) CIK: 0002052410 (see all company filings)

Type: 3 | Act: 34 | File No.: 001-41947 | Film No.: 25555511